Short-term investment fund

Citi Selected as Best Global Bank for Cash Management by Global Finance Magazine for 2023

Retrieved on: 
Mardi, avril 4, 2023
Finance, Consulting, Banking, Accounting, Professional Services, Grammy Award for Best Global Music Performance, Treasury, Global Finance (magazine), TTS, Financial system, Public sector, Organization, World Integrated Trade Solution, Growth, Short-term investment fund, Payment, Cryptocurrency, Bank, Citigroup

Citi has been named the Best Global Bank for Cash Management in 2023 by Global Finance Magazine.

Key Points: 
  • Citi has been named the Best Global Bank for Cash Management in 2023 by Global Finance Magazine.
  • The publication also named Citi the Best Global Provider of Short-Term Investments/Money Market Funds.
  • In addition, Citi earned recognition with multiple regional awards across Liquidity Management and Payments & Collections.
  • “Being recognized as Best Bank for Cash Management and Best Provider of Short-Term Investments/Money Market Funds by Global Finance is further validation of our global liquidity management networks and our steadfast commitment to helping clients better manage capital and liquidity risks, on the path to meeting critical objectives around growth, resiliency and efficiency.

Imago BioSciences Reports Third Quarter 2022 Financial Results and Provides Recent Business Updates

Retrieved on: 
Mercredi, novembre 9, 2022
Short-term investment fund, Blood, Sale, G&A, Company, Pancreatic serous cystadenoma, Treatment, Administration, MF, Review, Forward-looking statement, PV, Food, Society, Bone marrow, Genomics, Compliance, Cancer, Patient, COVID-19, Private Securities Litigation Reform Act, Regulation of tobacco by the U.S. Food and Drug Administration, Essential thrombocythemia, R, Polycythemia vera, EMA, Poster, ET, Growth, Hematology, FDA, GLOBE, Investment, Pandemic, Ruxolitinib, Good manufacturing practice, Annual report, Failure, Fast Track, Safety, LSD1, Priority, Research and development, European Medicines Agency, Pharmaceutical industry, Imago

REDWOOD CITY, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering and developing new medicines for the treatment of myeloproliferative neoplasms (MPNs) and other bone marrow diseases, today reported financial results for the third quarter ended September 30, 2022 and provided a corporate update.

Key Points: 
  • Imago continues to make progress in the clinical development of Bomedemstat for the treatment of MPNs including essential thrombocythemia (ET), polycythemia vera (PV) and myelofibrosis (MF).
  • Cash, Cash Equivalents, and Short-Term Investments: As of September30, 2022, Imago had cash, cash equivalents, and short-term investments of $178.4 million compared to $217.4 million as of December31, 2021.
  • Net Loss: Net loss for the quarter ended September30, 2022 was $16.8 million, compared to $11.7 million for the same period in 2021.
  • Imago is focused on improving the quality and length of life for patients with cancer and bone marrow diseases.